Drug Overview
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.
Table of Contents
1 Product Profiles- Xolair: Asthma
List of Figures
Figure 1: Asthma - current and future market dynamics analysis
Figure 2: The author’s drug assessment summary of Xolair in asthma
Figure 2: The author’s assessment summary of key marketed and pipeline drugs for asthma
Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Xolair drug profile
Table 2: Xolair pivotal trial data in asthma
Table 3: Xolair late-phase trial data in asthma
Table 4: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Companies Mentioned
- Roche
- Novartis
